title: Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay.
abstract: OBJECTIVE
  To evaluate the autoantibody profile in patients with primary biliary cirrhosis (PBC) using a new multiplexed line-blot assay specifically designed for the diagnosis of autoimmune liver diseases.
  
  
  METHODS
  Sera of 58 consecutive PBC patients and 191 disease controls (144 with autoimmune liver diseases other than PBC, and 67 with non-autoimmune chronic liver diseases) were tested by both the multiplexed line-blot Autoimmune Liver Disease Profile 2 (ALD2) and by IIF on HEp-2 cells and on rat kidney/liver/stomach tissues. ALD2 contains the following PBC-associated antigens: AMA-M2, natively purified from bovine heart; M2-E3, a recombinant fusion protein including the E2 subunits of PDC, BCOADC and OGDC; sp100, PML and gp210 recombinant proteins.
  
  
  RESULTS
  With the ALD2 assay, a positive reaction to AMA-M2, M2-E3, sp100, PML and gp210 in PBC patients was observed in 77.6%, 84.5%, 34.5%, 15.1% and 18.9%, respectively, of the PBC sera. The overall sensitivity and specificity for PBC were 98.3% and 93.7%. Using IIF, positivity rates to AMA, and to antinuclear autoantibodies with membranous/rim-like and multiple nuclear dot patterns were 86.2%, 8.6% and 22.4%, respectively. The overall sensitivity and specificity for PBC of the IIF method were 86.2% and 97.9%, respectively.
  
  
  CONCLUSIONS
  The ALD2 line-blot showed a good diagnostic accuracy for PBC and a higher sensitivity than the IIF method to detect sp100 and gp210 autoantibodies.
authors.affiliation: Allergologia e Immunologia Clinica, A.O. S. Maria degli Angeli, Pordenone, Italy. Electronic address: danilo.villalta@aopn.sanita.fvg.it.
authors.forename: Danilo
authors.initials: D
authors.lastname: Villalta
authors.affiliation: Laboratorio Analisi Chimico-Cliniche e Microbiologiche, ISMETT, Palermo, Italy.
authors.forename: Maria Concetta
authors.initials: MC
authors.lastname: Sorrentino
authors.affiliation: Dipartimento di Oncoematologia Pediatrica e Medicina Trasfusionale, Ospedale Bambino Gesù, Roma, Italy.
authors.forename: Elia
authors.initials: E
authors.lastname: Girolami
authors.affiliation: Patologia Clinica, Policlinico Consorziale di Bari, Italy.
authors.forename: Marilina
authors.initials: M
authors.lastname: Tampoia
authors.affiliation: Laboratorio Analisi Chimico-Cliniche, Ospedali Riuniti di Bergamo, Italy.
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Alessio
authors.affiliation: Patologia Clinica, Ospedale Buccheri La Ferla, Palermo, Italy.
authors.forename: Ignazio
authors.initials: I
authors.lastname: Brusca
authors.affiliation: Laboratorio Centrale, Ospedale Civile, Merano, BZ, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Daves
authors.affiliation: Dipartimento di Biotecnologie Mediche, Università di Siena, Italy.
authors.forename: Brunetta
authors.initials: B
authors.lastname: Porcelli
authors.affiliation: Patologia Clinica, Ospedale Cà Foncello, Treviso, Italy.
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Barberio
authors.affiliation: Patologia Clinica, Ospedale San Antonio, Tolmezzo, UD, Italy.
authors.forename: Nicola
authors.initials: N
authors.lastname: Bizzaro
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000276:immunology*; D001681:Biological Assay; D015415:Biomarkers / Q000097:blood*; D016022:Case-Control Studies; D002417:Cattle; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D051381:Rats; D012680:Sensitivity and Specificity; D055815:Young Adult
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D015415:Biomarkers
keywords: Anti-mitochondrial autoantibodies (AMA); Autoantibodies; Membranous/rim-like; Multiple nuclear dots (MND); gp210; sp100